Pegfilgrastim生物相似藥市場規模、佔有率和成長分析：按產品、給藥途徑、應用、通路和地區分類－2026-2033年產業預測

2024 年全球Pegfilgrastim生物相似藥市場價值為 35.2 億美元，預計到 2033 年將從 2025 年的 37.7 億美元成長至 65.2 億美元，預測期（2026-2033 年）複合年成長率為 7.1%。

全球Pegfilgrastim生物相似藥市場正經歷顯著成長，其主要驅動力是降低化療引起的嗜中性白血球低下症減少症治療成本的需求。原廠Pegfilgrastim價格高昂，令許多醫療系統難以負擔，因此促使人們轉向更具成本效益的生物相似藥。細胞培養技術和監管流程的進步加速了該領域的發展，使早期進入者能夠證明其產品與原廠藥療效相當。此外，醫院可節省的成本也進一步推動了這一轉變，這些節省下來的資金可以用於免疫療法等創新療法。隨著醫療機構擴大採用生物相似藥，競爭格局正在推動生產投資並加速法規核准，從而改善全球市場的准入並提升患者的治療效果。

全球Pegfilgrastim生物相似藥市場促進因素

隨著化療引起的嗜中性白血球低下症減少症治療費用日益增加，醫院正在尋求更經濟實惠的支持性治療方案。Pegfilgrastim生物相似藥在提供與原廠藥相當的療效的同時，價格更低，使患者更容易獲得必要的治療。這些替代療法有助於解決醫療機構面臨的預算限制，並支持以價值為導向的醫療模式，從而推動其應用。因此，醫療系統正致力於引入經濟高效的生物製藥，這促進了市場擴張，並為全球生物相似藥生產商帶來了持續成長的前景。這種轉變正在塑造一個充滿活力的市場格局，使製藥公司能夠拓展產品線，並增加對生物相似藥研發和監管流程的投資。

全球Pegfilgrastim生物相似藥市場的限制因素

全球Pegfilgrastim生物相似藥市場面臨諸多限制因素，主要源自於監管機構對生物相似藥的生物相似性提出的嚴格監管要求。這些要求需要大量的比較臨床數據，導致審查週期延長，審查更加嚴格。生產商必須投入大量資源進行直接比較試驗、進行分析表徵以及製定藥物安全監測計劃，所有這些都會增加研發成本並延緩上市進程。此類繁瑣的程序阻礙了中小企業進入市場，導致核准的生物相似藥數量有限，市場競爭活力下降。此外，為滿足區域法規要求而需提交單獨的申請，進一步延長了核准週期，阻礙了產品的快速市場滲透。

全球Pegfilgrastim生物相似藥市場趨勢

全球Pegfilgrastim生物相似藥市場呈現顯著成長態勢，其特徵是這些生物相似藥在多種腫瘤適應症的應用日益廣泛。腫瘤科醫師對Pegfilgrastim的安全性和有效性越來越有信心，因此將其納入固體癌和骨髓惡性腫瘤的標準化療方案中。醫院為最佳化庫存管理和減少治療延誤所做的努力進一步推動了這一趨勢，促使指南委員會制定了「生物相似藥優先」政策。因此，市場滲透率和可近性不斷提高，治療的連續性得到增強，全球患者獲得了更多接受重要癌症治療的機會。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Pegfilgrastim生物相似藥市場規模：依產品分類。

• Pegfilgrastim生物相似藥（參見：Neurasta）
• 穿戴式注射器

全球Pegfilgrastim生物相似藥市場規模：依給藥途徑分類

• 預填充式注射器
• 穿戴式注射器

全球Pegfilgrastim生物相似藥市場規模：依應用領域分類

• 化療引起的嗜中性白血球低下症（CIN）
• 嚴重慢性嗜嗜中性白血球低下症

全球Pegfilgrastim生物相似藥市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房
• 直接向患者銷售

全球Pegfilgrastim生物相似藥市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Amgen Inc.（Neulasta-originator）
• Coherus BioSciences（Udenyca）
• Mylan/Viatris（Fulphila）
• Sandoz（Novartis）-Ziextenzo
• Pfizer（Nyvepria）
• Samsung Bioepis（Fylnetra）
• Apotex
• Hospira（Pfizer）
• Dr. Reddy's Laboratories
• Teva Pharmaceutical
• Sun Pharmaceutical
• Celltrion Healthcare
• Biocon Biologics
• Lupin Biologics
• Hikma Pharmaceuticals
• Fresenius Kabi
• Amneal Pharmaceuticals
• Cipla BioTec
• Reliance Life Sciences
• Aurobindo Pharma（Eugia）

結論與建議

Global Pegfilgrastim Biosimilar Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 3.77 Billion in 2025 to USD 6.52 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).

The global pegfilgrastim biosimilar market is experiencing significant growth, driven by the need to lower chemotherapy-related neutropenia treatment costs. The high price of the original pegfilgrastim product has made it unaffordable for many healthcare systems, prompting a shift towards more cost-effective biosimilars. Advances in cell-culture technology and regulatory processes have accelerated this sector's development, allowing early entrants to demonstrate similar efficacy to the original drug. This transition is further incentivized by the potential savings hospitals can achieve, which can then be redirected to innovative therapies like immunotherapies. As healthcare providers increasingly adopt biosimilars, the competitive landscape fosters investments in manufacturing and encourages regulatory bodies to facilitate quicker approvals, enhancing market accessibility and improving patient outcomes globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pegfilgrastim Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pegfilgrastim Biosimilar Market Segments Analysis

Global pegfilgrastim biosimilar market is segmented by product, administration, application, distribution and region. Based on product, the market is segmented into pegfilgrastim biosimilar and on-body injector versions. Based on administration, the market is segmented into pre-filled syringe and on-body injector. Based on application, the market is segmented into chemotherapy-induced neutropenia (CIN) and severe chronic neutropenia. Based on distribution, the market is segmented into hospital pharmacies, specialty pharmacies and direct to patients. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pegfilgrastim Biosimilar Market

Increasing financial pressures associated with managing chemotherapy-induced neutropenia have led hospitals to seek more affordable supportive treatments. Pegfilgrastim biosimilars offer similar efficacy to the reference product but at a reduced cost, enabling greater patient access to essential therapy. These alternatives align with budgetary constraints faced by institutions and support value-based care models that encourage their adoption. As a result, healthcare systems are focusing on acquiring cost-effective biologics, which boosts market expansion and creates ongoing growth prospects for biosimilar manufacturers globally. This shift also allows pharmaceutical companies to broaden their product ranges and enhances their investment in biosimilar development and regulatory processes, fostering a dynamic market landscape.

Restraints in the Global Pegfilgrastim Biosimilar Market

The global pegfilgrastim biosimilar market faces significant restraints due to the stringent requirements imposed by regulatory authorities for establishing biosimilarity. These requirements necessitate extensive comparative clinical data, which lead to prolonged review periods and heightened scrutiny. Manufacturers must allocate considerable resources to conduct head-to-head trials, perform analytical characterization, and develop pharmacovigilance plans, all of which increase development costs and delay market entry. Such procedural complexities often discourage smaller companies from participating in the market, resulting in a limited number of approved biosimilars and consequently reducing competitive dynamics. Additionally, the need for separate submissions to meet various regional regulations further extends timelines and hampers rapid market penetration.

Market Trends of the Global Pegfilgrastim Biosimilar Market

The global Pegfilgrastim biosimilar market is witnessing a significant upward trend, characterized by the expanding adoption of these biosimilars in diverse oncology indications. Oncologists are increasingly confident in the safety and efficacy of pegfilgrastim biosimilars, leading to their integration into standard chemotherapy protocols for both solid tumors and hematologic malignancies. This trend is further bolstered by hospitals' efforts to optimize inventory management and minimize treatment delays, prompting the establishment of biosimilar-first policies by guideline committees. As a result, the market experiences enhanced penetration and accessibility, fostering improved therapeutic continuity and broadening patient access to critical cancer care worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pegfilgrastim Biosimilar Market Size by Product & CAGR (2026-2033)

• Market Overview
• Pegfilgrastim Biosimilar (Reference: Neulasta)
• On-Body Injector Versions

Global Pegfilgrastim Biosimilar Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Pre-filled Syringe
• On-Body Injector

Global Pegfilgrastim Biosimilar Market Size by Application & CAGR (2026-2033)

• Market Overview
• Chemotherapy-Induced Neutropenia (CIN)
• Severe Chronic Neutropenia

Global Pegfilgrastim Biosimilar Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Direct to Patients

Global Pegfilgrastim Biosimilar Market Size & CAGR (2026-2033)

• North America (Product, Administration, Application, Distribution)
  • US
  • Canada
• Europe (Product, Administration, Application, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Administration, Application, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Administration, Application, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Administration, Application, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (Neulasta - originator)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences (Udenyca)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan/Viatris (Fulphila)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis) - Ziextenzo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (Nyvepria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (Fylnetra)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hospira (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla BioTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (Eugia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations